drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00476 | DB00574 | 109 | 121 | [
"DDInter608",
"DDInter717"
] | Duloxetine | Fenfluramine | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Major | 2 | [
[
[
109,
25,
121
]
],
[
[
109,
25,
1670
],
[
1670,
63,
121
]
],
[
[
109,
63,
366
],
[
366,
24,
121
]
],
[
[
109,
24,
292
],
[
292,
6... | [
[
[
"Duloxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenfluramine"
]
],
[
[
"Duloxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u}... | Duloxetine may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Eptifibatide and Eptifibatide may ... |
DB00501 | DB00619 | 752 | 1,419 | [
"DDInter380",
"DDInter909"
] | Cimetidine | Imatinib | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
752,
24,
1419
]
],
[
[
752,
6,
4973
],
[
4973,
45,
1419
]
],
[
[
752,
21,
28762
],
[
28762,
60,
1419
]
],
[
[
752,
23,
1459
],
[
1459,... | [
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Cimetidine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Imatinib (Compound)
Cimetidine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Imatinib (Compound)
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Dolutegravir and Dolutegravir... |
DB00242 | DB00518 | 1,064 | 510 | [
"DDInter392",
"DDInter35"
] | Cladribine | Albendazole | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Major | 2 | [
[
[
1064,
25,
510
]
],
[
[
1064,
18,
5416
],
[
5416,
46,
510
]
],
[
[
1064,
7,
2857
],
[
2857,
46,
510
]
],
[
[
1064,
7,
2701
],
[
2701,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Albendazole"
]
],
[
[
"Cladribine",
"{u} (Compound) downregulates {v} (Gene)",
"KIF14"
],
[
"KIF14",
"{u} (Gene) is upregulated by {v} (Compound)",
... | Cladribine (Compound) downregulates KIF14 (Gene) and KIF14 (Gene) is upregulated by Albendazole (Compound)
Cladribine (Compound) upregulates CXCL2 (Gene) and CXCL2 (Gene) is upregulated by Albendazole (Compound)
Cladribine (Compound) upregulates CCNE2 (Gene) and CCNE2 (Gene) is downregulated by Albendazole (Compound)
C... |
DB00348 | DB13179 | 254 | 68 | [
"DDInter1300",
"DDInter1882"
] | Nitisinone | Troleandomycin | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | A macrolide antibiotic that is similar to erythromycin. | Moderate | 1 | [
[
[
254,
24,
68
]
],
[
[
254,
63,
1101
],
[
1101,
23,
68
]
],
[
[
254,
24,
1374
],
[
1374,
23,
68
]
],
[
[
254,
24,
1220
],
[
1220,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Troleandomycin
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abi... |
DB00316 | DB00352 | 474 | 482 | [
"DDInter14",
"DDInter1814"
] | Acetaminophen | Tioguanine | Acetaminophen (paracetamol), also commonly known as _Tylenol_, is the most commonly taken analgesic worldwide and is recommended as first-line therapy in pain conditions by the World Health Organization (WHO). It is also used for its antipyretic effects, helping to reduce fever. This drug was initially approved by the ... | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Moderate | 1 | [
[
[
474,
24,
482
]
],
[
[
474,
21,
28658
],
[
28658,
60,
482
]
],
[
[
474,
24,
322
],
[
322,
63,
482
]
],
[
[
474,
63,
912
],
[
912,
... | [
[
[
"Acetaminophen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Acetaminophen",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is ... | Acetaminophen (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Tioguanine (Compound)
Acetaminophen may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Tio... |
DB01068 | DB08899 | 1,565 | 129 | [
"DDInter411",
"DDInter649"
] | Clonazepam | Enzalutamide | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechan... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1565,
24,
129
]
],
[
[
1565,
6,
8374
],
[
8374,
45,
129
]
],
[
[
1565,
21,
28703
],
[
28703,
60,
129
]
],
[
[
1565,
63,
608
],
[
608,
... | [
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Clonazepam",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Clonazepam (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Clonazepam (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lid... |
DB00647 | DB06788 | 675 | 1,616 | [
"DDInter528",
"DDInter864"
] | Dextropropoxyphene | Histrelin | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
675,
24,
1616
]
],
[
[
675,
23,
112
],
[
112,
23,
1616
]
],
[
[
675,
24,
1342
],
[
1342,
24,
1616
]
],
[
[
675,
63,
1179
],
[
1179,
... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Dextropropoxyphene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"... | Dextropropoxyphene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Romi... |
DB01100 | DB09488 | 1,568 | 103 | [
"DDInter1470",
"DDInter23"
] | Pimozide | Acrivastine | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
1568,
24,
103
]
],
[
[
1568,
63,
85
],
[
85,
24,
103
]
],
[
[
1568,
25,
1264
],
[
1264,
24,
103
]
],
[
[
1568,
24,
537
],
[
537,
... | [
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"... | Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Pimozide may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a moderate in... |
DB00674 | DB12010 | 1,516 | 214 | [
"DDInter802",
"DDInter785"
] | Galantamine | Fostamatinib | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1516,
24,
214
]
],
[
[
1516,
24,
976
],
[
976,
24,
214
]
],
[
[
1516,
63,
322
],
[
322,
24,
214
]
],
[
[
1516,
24,
1017
],
[
1017,
... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
... | Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and ... |
DB01075 | DB11601 | 1,376 | 1,270 | [
"DDInter569",
"DDInter1889"
] | Diphenhydramine | Tuberculin purified protein derivative | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
1376,
24,
1270
]
],
[
[
1376,
63,
13
],
[
13,
24,
1270
]
],
[
[
1376,
24,
1053
],
[
1053,
24,
1270
]
],
[
[
1376,
74,
662
],
[
662,
... | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v... | Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Diphenhydramine may cause a moderate interaction that could exacerbate ... |
DB00580 | DB09133 | 311 | 1,527 | [
"DDInter1910",
"DDInter965"
] | Valdecoxib | Iothalamic acid | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Major | 2 | [
[
[
311,
25,
1527
]
],
[
[
311,
63,
91
],
[
91,
25,
1527
]
],
[
[
311,
24,
1512
],
[
1512,
25,
1527
]
],
[
[
311,
25,
629
],
[
629,
... | [
[
[
"Valdecoxib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vancomycin"
],
[
"Vanco... | Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may lead to a major life threatening interaction when taken with Iothalamic acid
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may l... |
DB00615 | DB00762 | 690 | 613 | [
"DDInter1589",
"DDInter973"
] | Rifabutin | Irinotecan | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Major | 2 | [
[
[
690,
25,
613
]
],
[
[
690,
6,
8374
],
[
8374,
45,
613
]
],
[
[
690,
7,
14278
],
[
14278,
46,
613
]
],
[
[
690,
18,
2183
],
[
2183,
... | [
[
[
"Rifabutin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Irinotecan"
]
],
[
[
"Rifabutin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Irinoteca... | Rifabutin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Irinotecan (Compound)
Rifabutin (Compound) upregulates PHKG2 (Gene) and PHKG2 (Gene) is upregulated by Irinotecan (Compound)
Rifabutin (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Irinotecan (Compound)
Rifabutin (Compou... |
DB00339 | DB01097 | 1,182 | 1,377 | [
"DDInter1547",
"DDInter1033"
] | Pyrazinamide | Leflunomide | A pyrazine that is used therapeutically as an antitubercular agent. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
1182,
25,
1377
]
],
[
[
1182,
6,
7950
],
[
7950,
45,
1377
]
],
[
[
1182,
21,
28701
],
[
28701,
60,
1377
]
],
[
[
1182,
24,
1613
],
[
1... | [
[
[
"Pyrazinamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Pyrazinamide",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Le... | Pyrazinamide (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Leflunomide (Compound)
Pyrazinamide (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Leflunomide (Compound)
Pyrazinamide may cause a moderate interaction that could exacerbate diseases when taken with Peginterf... |
DB04845 | DB06448 | 309 | 171 | [
"DDInter1001",
"DDInter1087"
] | Ixabepilone | Lonafarnib | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Moderate | 1 | [
[
[
309,
24,
171
]
],
[
[
309,
63,
63
],
[
63,
24,
171
]
],
[
[
309,
24,
310
],
[
310,
63,
171
]
],
[
[
309,
64,
1064
],
[
1064,
24,... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
],
[
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cab... |
DB00461 | DB00635 | 598 | 1,573 | [
"DDInter1254",
"DDInter1515"
] | Nabumetone | Prednisone | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
598,
24,
1573
]
],
[
[
598,
24,
175
],
[
175,
40,
1573
]
],
[
[
598,
63,
251
],
[
251,
1,
1573
]
],
[
[
598,
24,
167
],
[
167,
1... | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[... | Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Prednisone... |
DB00078 | DB06605 | 1,172 | 1,409 | [
"DDInter898",
"DDInter108"
] | Ibritumomab tiuxetan | Apixaban | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Major | 2 | [
[
[
1172,
25,
1409
]
],
[
[
1172,
23,
539
],
[
539,
62,
1409
]
],
[
[
1172,
24,
109
],
[
109,
24,
1409
]
],
[
[
1172,
64,
1057
],
[
1057,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
... | Ibritumomab tiuxetan may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Apixaban
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine ... |
DB00514 | DB00557 | 506 | 252 | [
"DDInter527",
"DDInter895"
] | Dextromethorphan | Hydroxyzine | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Moderate | 1 | [
[
[
506,
24,
252
]
],
[
[
506,
25,
851
],
[
851,
1,
252
]
],
[
[
506,
24,
1630
],
[
1630,
1,
252
]
],
[
[
506,
24,
623
],
[
623,
40,... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nefazodone"
],
[
... | Dextromethorphan may lead to a major life threatening interaction when taken with Nefazodone and Nefazodone (Compound) resembles Hydroxyzine (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Hydroxyzine (Compoun... |
DB00619 | DB01583 | 1,419 | 624 | [
"DDInter909",
"DDInter1075"
] | Imatinib | Liotrix | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal s... | Moderate | 1 | [
[
[
1419,
24,
624
]
],
[
[
1419,
63,
1152
],
[
1152,
1,
624
]
],
[
[
1419,
63,
542
],
[
542,
40,
624
]
],
[
[
1419,
6,
1829
],
[
1829,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Liotrix (Compound)
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine (Compound) resembles Liotrix (Compound)
... |
DB04911 | DB12141 | 968 | 971 | [
"DDInter1347",
"DDInter817"
] | Oritavancin | Gilteritinib | Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis). Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
968,
24,
971
]
],
[
[
968,
24,
466
],
[
466,
62,
971
]
],
[
[
968,
24,
1297
],
[
1297,
24,
971
]
],
[
[
968,
63,
1419
],
[
1419,
... | [
[
[
"Oritavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Oritavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Oritavancin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Oritavancin may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat an... |
DB01155 | DB06603 | 872 | 39 | [
"DDInter813",
"DDInter1387"
] | Gemifloxacin | Panobinostat | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
872,
25,
39
]
],
[
[
872,
62,
112
],
[
112,
23,
39
]
],
[
[
872,
63,
455
],
[
455,
24,
39
]
],
[
[
872,
62,
869
],
[
869,
24,
... | [
[
[
"Gemifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Gemifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Met... | Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol an... |
DB00054 | DB09030 | 1,432 | 840 | [
"DDInter6",
"DDInter1945"
] | Abciximab | Vorapaxar | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Major | 2 | [
[
[
1432,
25,
840
]
],
[
[
1432,
23,
944
],
[
944,
62,
840
]
],
[
[
1432,
24,
765
],
[
765,
24,
840
]
],
[
[
1432,
24,
1496
],
[
1496,
... | [
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Abciximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Abciximab may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Vorapaxar
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Hemin and Hemin may cause a mo... |
DB00560 | DB00682 | 753 | 126 | [
"DDInter1805",
"DDInter1951"
] | Tigecycline | Warfarin | Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17,... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
753,
24,
126
]
],
[
[
753,
40,
1620
],
[
1620,
63,
126
]
],
[
[
753,
1,
1669
],
[
1669,
63,
126
]
],
[
[
753,
40,
1572
],
[
1572,
... | [
[
[
"Tigecycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Tigecycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
],
[
"Tetracycline",
"{u} may cause a mod... | Tigecycline (Compound) resembles Tetracycline (Compound) and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Tigecycline (Compound) resembles Minocycline (Compound) and Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Warfa... |
DB00317 | DB00745 | 883 | 307 | [
"DDInter810",
"DDInter1236"
] | Gefitinib | Modafinil | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Minor | 0 | [
[
[
883,
23,
307
]
],
[
[
883,
63,
362
],
[
362,
40,
307
]
],
[
[
883,
24,
1236
],
[
1236,
40,
307
]
],
[
[
883,
6,
10215
],
[
10215,
... | [
[
[
"Gefitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"P... | Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Modafinil (Compound)
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine (Compound) resembles Modafinil (Compound)
... |
DB00208 | DB01238 | 1,018 | 673 | [
"DDInter1804",
"DDInter118"
] | Ticlopidine | Aripiprazole | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Moderate | 1 | [
[
[
1018,
24,
673
]
],
[
[
1018,
6,
12523
],
[
12523,
45,
673
]
],
[
[
1018,
21,
29209
],
[
29209,
60,
673
]
],
[
[
1018,
24,
1039
],
[
10... | [
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Ticlopidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compoun... | Ticlopidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Aripiprazole (Compound)
Ticlopidine (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Aripiprazole (Compound)
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramin... |
DB00827 | DB00912 | 646 | 473 | [
"DDInter383",
"DDInter1581"
] | Cinoxacin | Repaglinide | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Major | 2 | [
[
[
646,
25,
473
]
],
[
[
646,
21,
28778
],
[
28778,
60,
473
]
],
[
[
646,
63,
1512
],
[
1512,
24,
473
]
],
[
[
646,
24,
433
],
[
433,
... | [
[
[
"Cinoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Repaglinide"
]
],
[
[
"Cinoxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
"{u} (Side Effect) is ca... | Cinoxacin (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Repaglinide (Compound)
Cinoxacin may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when t... |
DB00261 | DB00543 | 702 | 87 | [
"DDInter93",
"DDInter82"
] | Anagrelide | Amoxapine | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Major | 2 | [
[
[
702,
25,
87
]
],
[
[
702,
24,
1119
],
[
1119,
1,
87
]
],
[
[
702,
25,
623
],
[
623,
40,
87
]
],
[
[
702,
18,
5833
],
[
5833,
46,... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amoxapine"
]
],
[
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlordiazepoxide"
],
[
"Chlor... | Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Chlordiazepoxide and Chlordiazepoxide (Compound) resembles Amoxapine (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Quetiapine and Quetiapine (Compound) resembles Amoxapine (Compound)
Anagr... |
DB01224 | DB13074 | 623 | 877 | [
"DDInter1553",
"DDInter1110"
] | Quetiapine | Macimorelin | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
623,
25,
877
]
],
[
[
623,
62,
112
],
[
112,
23,
877
]
],
[
[
623,
24,
1320
],
[
1320,
24,
877
]
],
[
[
623,
63,
85
],
[
85,
24,... | [
[
[
"Quetiapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Quetiapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Quetiapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elago... |
DB01001 | DB06707 | 688 | 584 | [
"DDInter1632",
"DDInter1060"
] | Salbutamol | Levonordefrin | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry. | Moderate | 1 | [
[
[
688,
24,
584
]
],
[
[
688,
63,
817
],
[
817,
40,
584
]
],
[
[
688,
24,
1354
],
[
1354,
1,
584
]
],
[
[
688,
1,
354
],
[
354,
40,... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonordefrin"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
],
[
... | Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine (Compound) resembles Levonordefrin (Compound)
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Droxidopa and Droxidopa (Compound) resembles Levonordefrin (Compound)
... |
DB00570 | DB00987 | 147 | 1,224 | [
"DDInter1936",
"DDInter461"
] | Vinblastine | Cytarabine (liposomal) | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Cytarabine can cause developmental toxicity according to an independent committee of scientific and health experts. | Moderate | 1 | [
[
[
147,
24,
1224
]
],
[
[
147,
5,
11555
],
[
11555,
44,
1224
]
],
[
[
147,
7,
2358
],
[
2358,
45,
1224
]
],
[
[
147,
6,
8803
],
[
8803,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Vinblastine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Dise... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine
Vinblastine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Cytarabine (Compound)
Vinblastine (Compound) upregulates CDA (Gene) and CDA (Gene) is bound by Cytarabine (Comp... |
DB08826 | DB11126 | 1,292 | 900 | [
"DDInter489",
"DDInter276"
] | Deferiprone | Calcium gluconate | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Calcium gluconate is used as mineral supplement and medication when there is insufficient calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets, consequences of hypocalcemia. It can also be taken by mouth but is not recommended by injection into a muscle. Calcium Gluconate Injecti... | Moderate | 1 | [
[
[
1292,
24,
900
]
],
[
[
1292,
63,
72
],
[
72,
24,
900
]
],
[
[
1292,
21,
28762
],
[
28762,
60,
729
],
[
729,
24,
900
]
],
[
[
1292,
... | [
[
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]... | Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Deferiprone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Penbutolo... |
DB01036 | DB04843 | 211 | 1,511 | [
"DDInter1832",
"DDInter1149"
] | Tolterodine | Mepenzolate | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
211,
24,
1511
]
],
[
[
211,
24,
537
],
[
537,
24,
1511
]
],
[
[
211,
63,
1192
],
[
1192,
24,
1511
]
],
[
[
211,
24,
1429
],
[
1429,
... | [
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and G... |
DB00584 | DB09104 | 610 | 286 | [
"DDInter638",
"DDInter1118"
] | Enalapril | Magnesium hydroxide | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypert... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Minor | 0 | [
[
[
610,
23,
286
]
],
[
[
610,
24,
820
],
[
820,
23,
286
]
],
[
[
610,
1,
1603
],
[
1603,
23,
286
]
],
[
[
610,
40,
743
],
[
743,
23... | [
[
[
"Enalapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Enalapril (Compound) resembles Captopril (Compound) and Captopril may cause a minor interaction that can... |
DB00889 | DB08918 | 1,133 | 41 | [
"DDInter840",
"DDInter1059"
] | Granisetron | Levomilnacipran | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Major | 2 | [
[
[
1133,
25,
41
]
],
[
[
1133,
25,
901
],
[
901,
40,
41
]
],
[
[
1133,
64,
1349
],
[
1349,
40,
41
]
],
[
[
1133,
6,
8374
],
[
8374,
... | [
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
... | Granisetron may lead to a major life threatening interaction when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Granisetron may lead to a major life threatening interaction when taken with Meperidine and Meperidine (Compound) resembles Levomilnacipran (Compound)
Granisetron (Com... |
DB00526 | DB06788 | 1,555 | 1,616 | [
"DDInter1355",
"DDInter864"
] | Oxaliplatin | Histrelin | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
1555,
24,
1616
]
],
[
[
1555,
24,
112
],
[
112,
23,
1616
]
],
[
[
1555,
23,
1247
],
[
1247,
23,
1616
]
],
[
[
1555,
24,
1664
],
[
1664... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Oxaliplatin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole a... |
DB08896 | DB08901 | 292 | 1,468 | [
"DDInter1576",
"DDInter1492"
] | Regorafenib | Ponatinib | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
292,
25,
1468
]
],
[
[
292,
6,
3188
],
[
3188,
45,
1468
]
],
[
[
292,
21,
29024
],
[
29024,
60,
1468
]
],
[
[
292,
23,
1135
],
[
1135,... | [
[
[
"Regorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Regorafenib",
"{u} (Compound) binds {v} (Gene)",
"RET"
],
[
"RET",
"{u} (Gene) is bound by {v} (Compound)",
"Ponatinib"
... | Regorafenib (Compound) binds RET (Gene) and RET (Gene) is bound by Ponatinib (Compound)
Regorafenib (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Ponatinib (Compound)
Regorafenib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxe... |
DB00836 | DB01044 | 543 | 246 | [
"DDInter1088",
"DDInter809"
] | Loperamide | Gatifloxacin | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Moderate | 1 | [
[
[
543,
24,
246
]
],
[
[
543,
24,
739
],
[
739,
1,
246
]
],
[
[
543,
63,
1176
],
[
1176,
1,
246
]
],
[
[
543,
24,
945
],
[
945,
40,... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gatifloxacin"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomefloxacin"
],
... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gatifloxacin (Compound)
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Gatifloxacin... |
DB00635 | DB09237 | 1,573 | 1,586 | [
"DDInter1515",
"DDInter1045"
] | Prednisone | Levamlodipine | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
1573,
24,
1586
]
],
[
[
1573,
63,
1648
],
[
1648,
24,
1586
]
],
[
[
1573,
24,
549
],
[
549,
24,
1586
]
],
[
[
1573,
40,
870
],
[
870,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin an... |
DB00284 | DB00938 | 1,647 | 455 | [
"DDInter11",
"DDInter1635"
] | Acarbose | Salmeterol | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
1647,
24,
455
]
],
[
[
1647,
24,
688
],
[
688,
63,
455
]
],
[
[
1647,
21,
28722
],
[
28722,
60,
455
]
],
[
[
1647,
24,
167
],
[
167,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Acarbose (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Salmeterol (Compound)
Acarbo... |
DB00312 | DB08816 | 1,023 | 578 | [
"DDInter1423",
"DDInter1802"
] | Pentobarbital | Ticagrelor | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
1023,
24,
578
]
],
[
[
1023,
6,
8374
],
[
8374,
45,
578
]
],
[
[
1023,
21,
28762
],
[
28762,
60,
578
]
],
[
[
1023,
24,
1135
],
[
1135... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Pentobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Pentobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Pentobarbital (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ticagrelor (Compound)
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol an... |
DB00222 | DB00852 | 245 | 1,445 | [
"DDInter825",
"DDInter1545"
] | Glimepiride | Pseudoephedrine | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Moderate | 1 | [
[
[
245,
24,
1445
]
],
[
[
245,
63,
73
],
[
73,
24,
1445
]
],
[
[
245,
24,
280
],
[
280,
40,
1445
]
],
[
[
245,
21,
28757
],
[
28757,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Mephentermin... |
DB00461 | DB01124 | 598 | 1,411 | [
"DDInter1254",
"DDInter1828"
] | Nabumetone | Tolbutamide | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
598,
24,
1411
]
],
[
[
598,
24,
959
],
[
959,
40,
1411
]
],
[
[
598,
63,
245
],
[
245,
40,
1411
]
],
[
[
598,
18,
16229
],
[
16229,
... | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound... |
DB00816 | DB12141 | 1,674 | 971 | [
"DDInter1346",
"DDInter817"
] | Orciprenaline | Gilteritinib | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1674,
24,
971
]
],
[
[
1674,
63,
485
],
[
485,
24,
971
]
],
[
[
1674,
24,
730
],
[
730,
63,
971
]
],
[
[
1674,
24,
820
],
[
820,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Deutetraben... |
DB00305 | DB14783 | 377 | 287 | [
"DDInter1232",
"DDInter574"
] | Mitomycin | Diroximel fumarate | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
377,
24,
287
]
],
[
[
377,
24,
995
],
[
995,
24,
287
]
],
[
[
377,
63,
599
],
[
599,
24,
287
]
],
[
[
377,
25,
970
],
[
970,
24,... | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
],
... | Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea and Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab a... |
DB00358 | DB00472 | 1,010 | 758 | [
"DDInter1140",
"DDInter758"
] | Mefloquine | Fluoxetine | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Moderate | 1 | [
[
[
1010,
24,
758
]
],
[
[
1010,
63,
847
],
[
847,
1,
758
]
],
[
[
1010,
6,
12523
],
[
12523,
45,
758
]
],
[
[
1010,
7,
1986
],
[
1986,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
],
[
... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Fluoxetine (Compound)
Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fluoxetine (Compound)
Mefloquine (Compound) upregulates INSIG1 (Gene) and INSIG1 (Gene... |
DB11691 | DB12267 | 1,499 | 1,476 | [
"DDInter1258",
"DDInter233"
] | Naldemedine | Brigatinib | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1499,
24,
1476
]
],
[
[
1499,
63,
1135
],
[
1135,
23,
1476
]
],
[
[
1499,
24,
800
],
[
800,
24,
1476
]
],
[
[
1499,
63,
79
],
[
79,
... | [
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib and Duvelisib... |
DB01057 | DB08897 | 1,318 | 1,429 | [
"DDInter615",
"DDInter22"
] | Echothiophate (ophthalmic) | Aclidinium | Ecothiopate is the phosphorothioate obtained by formal condensation of diethyl phosphate with N,N,N-trimethyl-2-sulfanylethanaminium. An irreversible acetylcholinesterase inhibitor, its iodide salt is used an ocular antihypertensive in the treatment of open-angle glaucoma, particularly when other drugs have proved inad... | Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. | Moderate | 1 | [
[
[
1318,
24,
1429
]
],
[
[
1318,
6,
10558
],
[
10558,
45,
1429
]
],
[
[
1318,
21,
28817
],
[
28817,
60,
1429
]
],
[
[
1318,
63,
662
],
[
... | [
[
[
"Echothiophate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Echothiophate",
"{u} (Compound) binds {v} (Gene)",
"BCHE"
],
[
"BCHE",
"{u} (Gene) is bound by {v} (Compound)... | Echothiophate may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Echothiophate (Compound) binds BCHE (Gene) and BCHE (Gene) is bound by Aclidinium (Compound)
Echothiophate (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Aclidinium (Com... |
DB00278 | DB00975 | 291 | 1,317 | [
"DDInter117",
"DDInter573"
] | Argatroban | Dipyridamole | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Major | 2 | [
[
[
291,
25,
1317
]
],
[
[
291,
21,
28809
],
[
28809,
60,
1317
]
],
[
[
291,
23,
1631
],
[
1631,
62,
1317
]
],
[
[
291,
24,
958
],
[
958,
... | [
[
[
"Argatroban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dipyridamole"
]
],
[
[
"Argatroban",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Co... | Argatroban (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Dipyridamole (Compound)
Argatroban may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Dipyridamole
... |
DB00365 | DB11248 | 839 | 1,193 | [
"DDInter842",
"DDInter1965"
] | Grepafloxacin | Zinc gluconate | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA . It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wi... | Moderate | 1 | [
[
[
839,
24,
1193
]
],
[
[
839,
24,
1096
],
[
1096,
23,
1193
]
],
[
[
839,
25,
167
],
[
167,
23,
1193
]
],
[
[
839,
23,
1307
],
[
1307,
... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid... | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Grepafloxacin may lead to a major life threatening interaction when taken with Hydrocortisone... |
DB00286 | DB08881 | 380 | 868 | [
"DDInter439",
"DDInter1925"
] | Conjugated estrogens | Vemurafenib | The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
380,
24,
868
]
],
[
[
380,
6,
8374
],
[
8374,
45,
868
]
],
[
[
380,
21,
28847
],
[
28847,
60,
868
]
],
[
[
380,
24,
1040
],
[
1040,
... | [
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Conjugated estrogens",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is boun... | Conjugated estrogens (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Conjugated estrogens (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Conjugated estrogens may cause a moderate interaction that could exacerbate diseas... |
DB05578 | DB06802 | 330 | 282 | [
"DDInter1566",
"DDInter1280"
] | Ramucirumab | Nepafenac (ophthalmic) | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Nepafenac is a monocarboxylic acid amide that is amfenac in which the carboxylic acid group has been converted into the corresponding carboxamide. It is a prodrug for amfenac, used in eye drops to treat pain and inflammation following cataract surgery. It has a role as a prodrug, a cyclooxygenase 2 inhibitor, a cycloox... | Moderate | 1 | [
[
[
330,
24,
282
]
],
[
[
330,
64,
886
],
[
886,
1,
282
]
],
[
[
330,
25,
39
],
[
39,
24,
282
]
],
[
[
330,
25,
1468
],
[
1468,
63,
... | [
[
[
"Ramucirumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nepafenac"
]
],
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ketorolac"
],
[
"Ketorolac"... | Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Nepafenac
Ramucirumab may lead to a major life threatening interaction when taken with Ketorolac and Ketorolac (Compound) resembles Nepafenac (Compound)
Ramucirumab may lead to a major life threatening interaction when taken wit... |
DB00619 | DB01610 | 1,419 | 248 | [
"DDInter909",
"DDInter1912"
] | Imatinib | Valganciclovir | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
1419,
24,
248
]
],
[
[
1419,
24,
563
],
[
563,
1,
248
]
],
[
[
1419,
21,
29209
],
[
29209,
60,
248
]
],
[
[
1419,
62,
1101
],
[
1101,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[
... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir (Compound) resembles Valganciclovir (Compound)
Imatinib (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Valganciclovir (Compound)
Imatinib may cause a minor interaction t... |
DB00305 | DB01177 | 377 | 77 | [
"DDInter1232",
"DDInter904"
] | Mitomycin | Idarubicin | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
377,
24,
77
]
],
[
[
377,
7,
6154
],
[
6154,
46,
77
]
],
[
[
377,
18,
5106
],
[
5106,
57,
77
]
],
[
[
377,
7,
5675
],
[
5675,
57... | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Mitomycin",
"{u} (Compound) upregulates {v} (Gene)",
"PSMB9"
],
[
"PSMB9",
"{u} (Gene) is upregulated by {v} (Com... | Mitomycin (Compound) upregulates PSMB9 (Gene) and PSMB9 (Gene) is upregulated by Idarubicin (Compound)
Mitomycin (Compound) downregulates ARID4B (Gene) and ARID4B (Gene) is downregulated by Idarubicin (Compound)
Mitomycin (Compound) upregulates KIAA0907 (Gene) and KIAA0907 (Gene) is downregulated by Idarubicin (Compoun... |
DB11718 | DB12457 | 927 | 1,180 | [
"DDInter640",
"DDInter1598"
] | Encorafenib | Rimegepant | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several p... | Moderate | 1 | [
[
[
927,
24,
1180
]
],
[
[
927,
24,
1619
],
[
1619,
24,
1180
]
],
[
[
927,
64,
1419
],
[
1419,
24,
1180
]
],
[
[
927,
25,
351
],
[
351,
... | [
[
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
... | Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Encorafenib may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a mo... |
DB01190 | DB01575 | 568 | 1,054 | [
"DDInter398",
"DDInter1005"
] | Clindamycin | Kaolin | Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bac... | Kaolin is a layered silicate mineral. Kaolin is used in ceramics, medicine, coated paper, as a food additive, in toothpaste, as a light diffusing material in white incandescent light bulbs, and in cosmetics. Until the early 1990s it was the active substance of anti-diarrhoea medicine Kaopectate. | Moderate | 1 | [
[
[
568,
24,
1054
]
],
[
[
568,
40,
1208
],
[
1208,
63,
1054
]
],
[
[
568,
21,
28719
],
[
28719,
60,
17
],
[
17,
23,
1054
]
],
[
[
568,
... | [
[
[
"Clindamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kaolin"
]
],
[
[
"Clindamycin",
"{u} (Compound) resembles {v} (Compound)",
"Lincomycin"
],
[
"Lincomycin",
"{u} may cause a moderate ... | Clindamycin (Compound) resembles Lincomycin (Compound) and Lincomycin may cause a moderate interaction that could exacerbate diseases when taken with Kaolin
Clindamycin (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Sotalol (Compound) and Sotalol may cause a minor interaction that can limit cl... |
DB00783 | DB11921 | 1,438 | 1,019 | [
"DDInter679",
"DDInter492"
] | Estradiol | Deflazacort | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
1438,
24,
1019
]
],
[
[
1438,
24,
959
],
[
959,
24,
1019
]
],
[
[
1438,
24,
1619
],
[
1619,
63,
1019
]
],
[
[
1438,
1,
890
],
[
890,
... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib ... |
DB01174 | DB09038 | 697 | 1,450 | [
"DDInter1442",
"DDInter636"
] | Phenobarbital | Empagliflozin | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
697,
24,
1450
]
],
[
[
697,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
697,
25,
1017
],
[
1017,
63,
1450
]
],
[
[
697,
40,
759
],
[
759,
... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
... | Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Phenobarbital may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatin... |
DB01359 | DB01377 | 729 | 1,283 | [
"DDInter1417",
"DDInter1119"
] | Penbutolol | Magnesium oxide | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Minor | 0 | [
[
[
729,
23,
1283
]
],
[
[
729,
40,
461
],
[
461,
23,
1283
]
],
[
[
729,
63,
167
],
[
167,
23,
1283
]
],
[
[
729,
1,
699
],
[
699,
2... | [
[
[
"Penbutolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Penbutolol",
"{u} (Compound) resembles {v} (Compound)",
"Timolol"
],
[
"Timolol",
"{u} may cause a minor inte... | Penbutolol (Compound) resembles Timolol (Compound) and Timolol may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can... |
DB01064 | DB06402 | 1,148 | 1,079 | [
"DDInter987",
"DDInter1756"
] | Isoprenaline | Telavancin | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Moderate | 1 | [
[
[
1148,
24,
1079
]
],
[
[
1148,
21,
28722
],
[
28722,
60,
1079
]
],
[
[
1148,
63,
1181
],
[
1181,
24,
1079
]
],
[
[
1148,
24,
124
],
[
1... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Isoprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused... | Isoprenaline (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Telavancin (Compound)
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Telavan... |
DB04932 | DB08875 | 1,564 | 1,618 | [
"DDInter491",
"DDInter262"
] | Defibrotide | Cabozantinib | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Da... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1564,
25,
1618
]
],
[
[
1564,
24,
41
],
[
41,
63,
1618
]
],
[
[
1564,
25,
283
],
[
283,
63,
1618
]
],
[
[
1564,
63,
222
],
[
222,
... | [
[
[
"Defibrotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Defibrotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"L... | Defibrotide may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Defibrotide may lead to a major life threatening interaction when taken with Fedratinib and Fedrati... |
DB00620 | DB11113 | 175 | 657 | [
"DDInter1855",
"DDInter307"
] | Triamcinolone | Castor oil | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
175,
24,
657
]
],
[
[
175,
24,
1326
],
[
1326,
24,
657
]
],
[
[
175,
40,
891
],
[
891,
24,
657
]
],
[
[
175,
25,
739
],
[
739,
2... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
],... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide and Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Triamcinolone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate intera... |
DB00679 | DB00687 | 684 | 870 | [
"DDInter1796",
"DDInter747"
] | Thioridazine | Fludrocortisone | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
684,
24,
870
]
],
[
[
684,
24,
167
],
[
167,
40,
870
]
],
[
[
684,
21,
29087
],
[
29087,
60,
870
]
],
[
[
684,
23,
115
],
[
115,
... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
... | Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Fludrocortisone (Compound)
Thioridazine (Compound) causes Amenorrhoea (Side Effect) and Amenorrhoea (Side Effect) is caused by Fludrocortisone (Compound)
Thioridazine may c... |
DB05812 | DB09061 | 1,374 | 1,627 | [
"DDInter8",
"DDInter284"
] | Abiraterone | Cannabidiol | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
1374,
24,
1627
]
],
[
[
1374,
23,
760
],
[
760,
62,
1627
]
],
[
[
1374,
63,
609
],
[
609,
23,
1627
]
],
[
[
1374,
24,
384
],
[
384,
... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
],
[
... | Abiraterone may cause a minor interaction that can limit clinical effects when taken with Cobicistat and Cobicistat may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Cla... |
DB01017 | DB01060 | 1,669 | 319 | [
"DDInter1224",
"DDInter83"
] | Minocycline | Amoxicillin | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to [penicillin] and [ampicillin], but leads to higher serum concentrations than ampicillin. Amoxicillin was granted FDA approval on 18 January 1974. | Moderate | 1 | [
[
[
1669,
24,
319
]
],
[
[
1669,
63,
1249
],
[
1249,
40,
319
]
],
[
[
1669,
24,
950
],
[
950,
1,
319
]
],
[
[
1669,
63,
703
],
[
703,
... | [
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxicillin"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nafcillin"
],
[
... | Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin (Compound) resembles Amoxicillin (Compound)
Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Cloxacillin and Cloxacillin (Compound) resembles Amoxicillin (Compou... |
DB00358 | DB01087 | 1,010 | 1,520 | [
"DDInter1140",
"DDInter1520"
] | Mefloquine | Primaquine | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Moderate | 1 | [
[
[
1010,
24,
1520
]
],
[
[
1010,
25,
1487
],
[
1487,
64,
1520
]
],
[
[
1010,
6,
12523
],
[
12523,
45,
1520
]
],
[
[
1010,
21,
28722
],
[
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hy... | Mefloquine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Primaquine
Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Primaquine (Compound)
Mefloquine (Compound) causes Nau... |
DB00350 | DB01037 | 1,214 | 1,161 | [
"DDInter1226",
"DDInter1653"
] | Minoxidil | Selegiline | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual... | Moderate | 1 | [
[
[
1214,
24,
1161
]
],
[
[
1214,
24,
551
],
[
551,
1,
1161
]
],
[
[
1214,
24,
104
],
[
104,
24,
1161
]
],
[
[
1214,
24,
401
],
[
401,
... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selegiline"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
[
... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Selegiline (Compound)
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that cou... |
DB01005 | DB11627 | 995 | 1,367 | [
"DDInter894",
"DDInter860"
] | Hydroxyurea | Hepatitis B Vaccine (Recombinant) | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Moderate | 1 | [
[
[
995,
24,
1367
]
],
[
[
995,
63,
1648
],
[
1648,
24,
1367
]
],
[
[
995,
64,
1064
],
[
1064,
24,
1367
]
],
[
[
995,
24,
259
],
[
259,
... | [
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis B Vaccine (Recombinant)"
]
],
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Al... | Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Hydroxyurea may lead to a major life threatening interaction when taken with Cladribin... |
DB01044 | DB08907 | 246 | 1,344 | [
"DDInter809",
"DDInter280"
] | Gatifloxacin | Canagliflozin | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Major | 2 | [
[
[
246,
25,
1344
]
],
[
[
246,
25,
549
],
[
549,
1,
1344
]
],
[
[
246,
6,
1829
],
[
1829,
45,
1344
]
],
[
[
246,
21,
28873
],
[
28873,
... | [
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Canagliflozin"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",... | Gatifloxacin may lead to a major life threatening interaction when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Gatifloxacin (Compound) binds ALB (Gene) and ALB (Gene) is bound by Canagliflozin (Compound)
Gatifloxacin (Compound) causes Pancreatitis (Side Effect) and Pancreati... |
DB12834 | DB15965 | 148 | 1,330 | [
"DDInter1649",
"DDInter1270"
] | Secnidazole | Naxitamab | Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including and, but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive a... | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Moderate | 1 | [
[
[
148,
24,
1330
]
],
[
[
148,
63,
14
],
[
14,
24,
1330
]
],
[
[
148,
63,
375
],
[
375,
25,
1330
]
],
[
[
148,
63,
14
],
[
14,
63,
... | [
[
[
"Secnidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Secnidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[... | Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab peg... |
DB00019 | DB09073 | 1,257 | 951 | [
"DDInter1405",
"DDInter1379"
] | Pegfilgrastim | Palbociclib | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
1257,
24,
951
]
],
[
[
1257,
24,
134
],
[
134,
24,
951
]
],
[
[
1257,
24,
405
],
[
405,
63,
951
]
],
[
[
1257,
25,
1064
],
[
1064,
... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutini... |
DB00694 | DB01142 | 51 | 1,264 | [
"DDInter485",
"DDInter593"
] | Daunorubicin | Doxepin | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
51,
24,
1264
]
],
[
[
51,
63,
508
],
[
508,
24,
1264
]
],
[
[
51,
24,
401
],
[
401,
24,
1264
]
],
[
[
51,
6,
4973
],
[
4973,
45,... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Prome... |
DB01069 | DB01452 | 401 | 993 | [
"DDInter1533",
"DDInter532"
] | Promethazine | Diamorphine | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is ... | Moderate | 1 | [
[
[
401,
24,
993
]
],
[
[
401,
63,
421
],
[
421,
40,
993
]
],
[
[
401,
63,
475
],
[
475,
25,
993
]
],
[
[
401,
24,
22
],
[
22,
23,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diamorphine"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Diamorphine (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening... |
DB00106 | DB00916 | 618 | 112 | [
"DDInter4",
"DDInter1202"
] | Abarelix | Metronidazole | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Minor | 0 | [
[
[
618,
23,
112
]
],
[
[
618,
24,
847
],
[
847,
23,
112
]
],
[
[
618,
24,
843
],
[
843,
62,
112
]
],
[
[
618,
25,
996
],
[
996,
62,... | [
[
[
"Abarelix",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
],
[
... | Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine and Tetr... |
DB00969 | DB06803 | 2 | 769 | [
"DDInter52",
"DDInter1288"
] | Alosetron | Niclosamide | Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US marke... | Niclosamide is an antihelminthic used for the treatment of tapeworm infections. Helminths (worms) are multicellular organisms that infect very large numbers of humans and cause a broad range of diseases. Over 1 billion people are infected with intestinal nematodes, and many millions are infected with filarial nematodes... | Moderate | 1 | [
[
[
2,
24,
769
]
],
[
[
2,
6,
7950
],
[
7950,
45,
769
]
],
[
[
2,
6,
7950
],
[
7950,
45,
109
],
[
109,
24,
769
]
],
[
[
2,
1,
... | [
[
[
"Alosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niclosamide"
]
],
[
[
"Alosetron",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Alosetron (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Niclosamide (Compound)
Alosetron (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Niclosamide
Alosetron (Compound) resem... |
DB08893 | DB08899 | 271 | 129 | [
"DDInter1229",
"DDInter649"
] | Mirabegron | Enzalutamide | Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and [darifenacin], it lacks significa... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Minor | 0 | [
[
[
271,
23,
129
]
],
[
[
271,
62,
918
],
[
918,
1,
129
]
],
[
[
271,
6,
8374
],
[
8374,
45,
129
]
],
[
[
271,
21,
28703
],
[
28703,
... | [
[
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enzalutamide"
]
],
[
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bicalutamide"
],
[
... | Mirabegron may cause a minor interaction that can limit clinical effects when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Mirabegron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Mirabegron (Compound) causes Pruritus (Side Effect) and Prur... |
DB01033 | DB01177 | 328 | 77 | [
"DDInter1156",
"DDInter904"
] | Mercaptopurine | Idarubicin | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
328,
24,
77
]
],
[
[
328,
5,
11555
],
[
11555,
44,
77
]
],
[
[
328,
6,
11104
],
[
11104,
46,
77
]
],
[
[
328,
21,
28803
],
[
28803,
... | [
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Mercaptopurine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u}... | Mercaptopurine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Idarubicin (Compound)
Mercaptopurine (Compound) binds TPMT (Gene) and TPMT (Gene) is upregulated by Idarubicin (Compound)
Mercaptopurine (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is cause... |
DB00970 | DB01005 | 0 | 995 | [
"DDInter466",
"DDInter894"
] | Dactinomycin | Hydroxyurea | A compound composed of a two cyclic peptides attached to a phenoxazine that is derived from streptomyces parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also d... | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Moderate | 1 | [
[
[
0,
24,
995
]
],
[
[
0,
21,
28845
],
[
28845,
60,
995
]
],
[
[
0,
62,
1299
],
[
1299,
23,
995
]
],
[
[
0,
23,
945
],
[
945,
62,
... | [
[
[
"Dactinomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyurea"
]
],
[
[
"Dactinomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema"
],
[
"Oedema",
"{u} (Side Effect) is cause... | Dactinomycin (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Hydroxyurea (Compound)
Dactinomycin may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin and Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Hydrox... |
DB00197 | DB00294 | 1,324 | 1,336 | [
"DDInter1881",
"DDInter701"
] | Troglitazone | Etonogestrel | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Moderate | 1 | [
[
[
1324,
24,
1336
]
],
[
[
1324,
24,
566
],
[
566,
1,
1336
]
],
[
[
1324,
24,
1561
],
[
1561,
40,
1336
]
],
[
[
1324,
24,
1130
],
[
1130,... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etonogestrel"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonorgestrel"
]... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Levonorgestrel and Levonorgestrel (Compound) resembles Etonogestrel (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Eton... |
DB00524 | DB01156 | 811 | 593 | [
"DDInter1199",
"DDInter252"
] | Metolazone | Bupropion | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Moderate | 1 | [
[
[
811,
24,
593
]
],
[
[
811,
21,
28757
],
[
28757,
60,
593
]
],
[
[
811,
23,
126
],
[
126,
24,
593
]
],
[
[
811,
1,
1605
],
[
1605,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Metolazone",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is cause... | Metolazone (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Bupropion (Compound)
Metolazone may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Meto... |
DB00285 | DB00662 | 1,100 | 717 | [
"DDInter1927",
"DDInter1873"
] | Venlafaxine | Trimethobenzamide | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Moderate | 1 | [
[
[
1100,
24,
717
]
],
[
[
1100,
25,
1425
],
[
1425,
40,
717
]
],
[
[
1100,
21,
28762
],
[
28762,
60,
717
]
],
[
[
1100,
24,
1594
],
[
159... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Ci... | Venlafaxine may lead to a major life threatening interaction when taken with Cisapride and Cisapride (Compound) resembles Trimethobenzamide (Compound)
Venlafaxine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Trimethobenzamide (Compound)
Venlafaxine may cause a moderate interaction th... |
DB00427 | DB01589 | 1,233 | 481 | [
"DDInter1879",
"DDInter1552"
] | Triprolidine | Quazepam | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Moderate | 1 | [
[
[
1233,
24,
481
]
],
[
[
1233,
24,
1216
],
[
1216,
1,
481
]
],
[
[
1233,
63,
523
],
[
523,
1,
481
]
],
[
[
1233,
63,
905
],
[
905,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Quazepam (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam and Alprazolam (Compound) resembles Quazepam (Compound)
... |
DB11166 | DB11703 | 18 | 405 | [
"DDInter104",
"DDInter9"
] | Antithrombin Alfa | Acalabrutinib | Antithrombin Alfa is a recombinant antithrombin, an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
18,
25,
405
]
],
[
[
18,
63,
557
],
[
557,
24,
405
]
],
[
[
18,
24,
738
],
[
738,
63,
405
]
],
[
[
18,
64,
802
],
[
802,
25,
... | [
[
[
"Antithrombin Alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Antithrombin Alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
],
... | Antithrombin Alfa may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Antithrombin Alfa may cause a moderate interaction that could exacerbate diseases when tak... |
DB00731 | DB01124 | 1,144 | 1,411 | [
"DDInter1269",
"DDInter1828"
] | Nateglinide | Tolbutamide | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
1144,
24,
1411
]
],
[
[
1144,
24,
959
],
[
959,
40,
1411
]
],
[
[
1144,
24,
824
],
[
824,
24,
1411
]
],
[
[
1144,
63,
245
],
[
245,
... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Probenecid and Probenecid may cause a moderate interaction that coul... |
DB00065 | DB09036 | 581 | 812 | [
"DDInter923",
"DDInter1668"
] | Infliximab | Siltuximab | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Major | 2 | [
[
[
581,
25,
812
]
],
[
[
581,
23,
1193
],
[
1193,
62,
812
]
],
[
[
581,
23,
1461
],
[
1461,
23,
812
]
],
[
[
581,
25,
287
],
[
287,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Siltuximab"
]
],
[
[
"Infliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc glu... | Infliximab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Siltuximab
Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitam... |
DB00390 | DB00586 | 1,252 | 1,512 | [
"DDInter554",
"DDInter537"
] | Digoxin | Diclofenac | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Moderate | 1 | [
[
[
1252,
24,
1512
]
],
[
[
1252,
6,
8374
],
[
8374,
45,
1512
]
],
[
[
1252,
7,
7720
],
[
7720,
45,
1512
]
],
[
[
1252,
21,
29231
],
[
292... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Digoxin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Digoxin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Diclofenac (Compound)
Digoxin (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Diclofenac (Compound)
Digoxin (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Diclofenac (Compound)
Digoxin... |
DB04845 | DB05273 | 309 | 507 | [
"DDInter1001",
"DDInter1638"
] | Ixabepilone | Samarium (153Sm) lexidronam | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Major | 2 | [
[
[
309,
25,
507
]
],
[
[
309,
63,
248
],
[
248,
24,
507
]
],
[
[
309,
24,
270
],
[
270,
63,
507
]
],
[
[
309,
63,
1101
],
[
1101,
2... | [
[
[
"Ixabepilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken... |
DB00197 | DB06237 | 1,324 | 438 | [
"DDInter1881",
"DDInter141"
] | Troglitazone | Avanafil | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively lower risk of visual ... | Moderate | 1 | [
[
[
1324,
24,
438
]
],
[
[
1324,
24,
1017
],
[
1017,
63,
438
]
],
[
[
1324,
23,
1101
],
[
1101,
24,
438
]
],
[
[
1324,
24,
1220
],
[
1220,... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avanafil"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Avanafil
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexaro... |
DB00486 | DB14509 | 1,614 | 1,399 | [
"DDInter1253",
"DDInter1081"
] | Nabilone | Lithium carbonate | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1614,
24,
1399
]
],
[
[
1614,
24,
506
],
[
506,
24,
1399
]
],
[
[
1614,
63,
475
],
[
475,
24,
1399
]
],
[
[
1614,
40,
530
],
[
530,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Morphi... |
DB00208 | DB00252 | 1,018 | 362 | [
"DDInter1804",
"DDInter1460"
] | Ticlopidine | Phenytoin | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Moderate | 1 | [
[
[
1018,
24,
362
]
],
[
[
1018,
23,
697
],
[
697,
40,
362
]
],
[
[
1018,
24,
126
],
[
126,
63,
362
]
],
[
[
1018,
24,
1236
],
[
1236,
... | [
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
]
],
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenobarbital"
],
[
... | Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Phenobarbital and Phenobarbital (Compound) resembles Phenytoin (Compound)
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that coul... |
DB00321 | DB00332 | 21 | 1,089 | [
"DDInter78",
"DDInter970"
] | Amitriptyline | Ipratropium | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its... | Moderate | 1 | [
[
[
21,
24,
1089
]
],
[
[
21,
63,
352
],
[
352,
24,
1089
]
],
[
[
21,
24,
85
],
[
85,
63,
1089
]
],
[
[
21,
6,
4304
],
[
4304,
45,
... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipratropium"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
... | Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Ipratropium
Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atrop... |
DB00853 | DB01208 | 1,686 | 945 | [
"DDInter1762",
"DDInter1705"
] | Temozolomide | Sparfloxacin | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Minor | 0 | [
[
[
1686,
23,
945
]
],
[
[
1686,
23,
739
],
[
739,
1,
945
]
],
[
[
1686,
62,
1176
],
[
1176,
1,
945
]
],
[
[
1686,
21,
28787
],
[
28787,
... | [
[
[
"Temozolomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
]
],
[
[
"Temozolomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lomefloxacin"
],
... | Temozolomide may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Temozolomide may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Sparfloxacin... |
DB00465 | DB00758 | 886 | 1,347 | [
"DDInter1010",
"DDInter413"
] | Ketorolac | Clopidogrel | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Moderate | 1 | [
[
[
886,
24,
1347
]
],
[
[
886,
63,
1018
],
[
1018,
25,
1347
]
],
[
[
886,
7,
16662
],
[
16662,
46,
1347
]
],
[
[
886,
18,
10375
],
[
1037... | [
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
... | Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may lead to a major life threatening interaction when taken with Clopidogrel
Ketorolac (Compound) upregulates SQRDL (Gene) and SQRDL (Gene) is upregulated by Clopidogrel (Compound)
Ketorolac (Compound) ... |
DB00376 | DB00748 | 1,105 | 662 | [
"DDInter1870",
"DDInter297"
] | Trihexyphenidyl | Carbinoxamine | Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is n... | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
1105,
24,
662
]
],
[
[
1105,
63,
1594
],
[
1594,
24,
662
]
],
[
[
1105,
24,
128
],
[
128,
24,
662
]
],
[
[
1105,
1,
11268
],
[
11268,
... | [
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
... | Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Dexbromp... |
DB06819 | DB11921 | 754 | 1,019 | [
"DDInter1452",
"DDInter492"
] | Phenylbutyric acid | Deflazacort | Phenylbutyric acid is a fatty acid and a derivative of [butyric acid] naturally produced by colonic bacteria fermentation. It demonstrates a number of cellular and biological effects, such as relieving inflammation and acting as a chemical chaperone. It is used to treat genetic metabolic syndromes, neuropathies, and ur... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
754,
24,
1019
]
],
[
[
754,
63,
1220
],
[
1220,
25,
1019
]
],
[
[
754,
63,
1220
],
[
1220,
62,
1072
],
[
1072,
23,
1019
]
],
[
[
754,
... | [
[
[
"Phenylbutyric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Phenylbutyric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethas... | Phenylbutyric acid may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Deflazacort
Phenylbutyric acid may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone... |
DB01168 | DB01576 | 1,053 | 93 | [
"DDInter1526",
"DDInter526"
] | Procarbazine | Dextroamphetamine | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Dextroamphetamine is the dextrorotatory enantiomer of amphetamine. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label]. | Major | 2 | [
[
[
1053,
25,
93
]
],
[
[
1053,
64,
73
],
[
73,
1,
93
]
],
[
[
1053,
64,
80
],
[
80,
40,
93
]
],
[
[
1053,
25,
1529
],
[
1529,
40,
... | [
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextroamphetamine"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phentermine"
],
[
"Phentermine",... | Procarbazine may lead to a major life threatening interaction when taken with Phentermine and Phentermine (Compound) resembles Dextroamphetamine (Compound)
Procarbazine may lead to a major life threatening interaction when taken with Amphetamine and Amphetamine (Compound) resembles Dextroamphetamine (Compound)
Procarba... |
DB06335 | DB12332 | 761 | 1,619 | [
"DDInter1646",
"DDInter1626"
] | Saxagliptin | Rucaparib | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
761,
24,
1619
]
],
[
[
761,
63,
222
],
[
222,
23,
1619
]
],
[
[
761,
62,
307
],
[
307,
23,
1619
]
],
[
[
761,
24,
154
],
[
154,
... | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Saxagliptin may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafini... |
DB00497 | DB00673 | 828 | 723 | [
"DDInter1366",
"DDInter112"
] | Oxycodone | Aprepitant | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Major | 2 | [
[
[
828,
25,
723
]
],
[
[
828,
6,
6799
],
[
6799,
45,
723
]
],
[
[
828,
21,
29257
],
[
29257,
60,
723
]
],
[
[
828,
24,
222
],
[
222,
... | [
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aprepitant"
]
],
[
[
"Oxycodone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7"
],
[
"CYP3A7",
"{u} (Gene) is bound by {v} (Compound)",
"Aprepitan... | Oxycodone (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Aprepitant (Compound)
Oxycodone (Compound) causes Body temperature decreased (Side Effect) and Body temperature decreased (Side Effect) is caused by Aprepitant (Compound)
Oxycodone may cause a moderate interaction that could exacerbate diseases when... |
DB06605 | DB12130 | 1,409 | 1,017 | [
"DDInter108",
"DDInter1094"
] | Apixaban | Lorlatinib | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1409,
24,
1017
]
],
[
[
1409,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
1409,
63,
409
],
[
409,
24,
1017
]
],
[
[
1409,
25,
1421
],
[
1421... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine m... |
DB00334 | DB00468 | 867 | 1,424 | [
"DDInter1326",
"DDInter1557"
] | Olanzapine | Quinine | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Moderate | 1 | [
[
[
867,
24,
1424
]
],
[
[
867,
6,
6017
],
[
6017,
45,
1424
]
],
[
[
867,
23,
112
],
[
112,
62,
1424
]
],
[
[
867,
24,
1254
],
[
1254,
... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
]
],
[
[
"Olanzapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Olanzapine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Quinine (Compound)
Olanzapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Quinine
Olanzapine may cause a... |
DB04948 | DB09268 | 1,084 | 1,662 | [
"DDInter1083",
"DDInter1464"
] | Lofexidine | Picosulfuric acid | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1084,
24,
1662
]
],
[
[
1084,
24,
484
],
[
484,
63,
1662
]
],
[
[
1084,
25,
1618
],
[
1618,
24,
1662
]
],
[
[
1084,
24,
1491
],
[
1491... | [
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
... | Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Lofexidine may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantin... |
DB08865 | DB09034 | 1,593 | 1,313 | [
"DDInter448",
"DDInter1733"
] | Crizotinib | Suvorexant | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Major | 2 | [
[
[
1593,
25,
1313
]
],
[
[
1593,
25,
1135
],
[
1135,
62,
1313
]
],
[
[
1593,
64,
1213
],
[
1213,
24,
1313
]
],
[
[
1593,
25,
1619
],
[
16... | [
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Suvorexant"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may... | Crizotinib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Suvorexant
Crizotinib may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interactio... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.